BioMérieux: 9m sales up by less than 8%

(CercleFinance.com) - bioMérieux reports 9m 2024 sales of E2.
87bn, up 7.6% as reported and up 10.3% organically, driven by the growth drivers of the GO28 strategic plan, up 12%.

The in vitro diagnostics specialist also highlights the strong contribution of the Biofire respiratory (+14%) and non-respiratory (+18%) panels, as well as 9% increases in sales in microbiology and industrial applications.

bioMérieux confirms its targets for 2024 of a 12% to 17% increase in operating profit from ordinary activities (ROCC), and organic sales growth of 8% to 10%, both at constant exchange rates.


Copyright (c) 2024 CercleFinance.com. All rights reserved.